Osiris Therapeutics, Inc. Common Stock
OSIR
OSIR was delisted on the 16th of April, 2019.
67 hedge funds and large institutions have $133M invested in Osiris Therapeutics, Inc. Common Stock in 2014 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 24 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
17% more capital invested
Capital invested by funds: $113M → $133M (+$19.4M)
6% more funds holding
Funds holding: 63 → 67 (+4)
8% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 24
74% less call options, than puts
Call options by funds: $1.22M | Put options by funds: $4.68M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$2.19M |
| 2 |
DM
Deerfield Management
New York
|
+$639K |
| 3 |
Renaissance Technologies
New York
|
+$572K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$384K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$250K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.47M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$1.25M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$905K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$617K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$313K |
OSIR Hedge Fund Activity: Q2 2014 in Review
67 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q2 2014, worth a combined $133M — up 17% from $113M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new OSIR positions and 6 closed out — a net gain of 4 holders — while 22 added to existing stakes and 24 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $2.19M. The largest seller was Fidelity Investments, cutting an estimated $2.47M.
- 67 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q2 2014, up from 63 in Q1 2014.
- Funds reported $133M of Osiris Therapeutics, Inc. Common Stock stock for Q2 2014, up 17% quarter-over-quarter.
- 10 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q2 2014 and 6 closed out, a net change of +4 holders.
- The largest Osiris Therapeutics, Inc. Common Stock buyer in Q2 2014 was Baker Bros. Advisors, an estimated $2.19M added.
- The largest Osiris Therapeutics, Inc. Common Stock seller in Q2 2014 was Fidelity Investments, an estimated $2.47M sold.
Based on aggregated 13F filings for Q2 2014.